Human CellExp™ OX40 / TNFRSF4 / CD134, Fc Tag, rat recombinant | P1151

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

P1151 | Human CellExp OX40 / TNFRSF4 / CD134 Fc Tag rat recombinant DataSheet

Biomolecule/Target: Tnfrsf4

Synonyms: TNFRSF4, OX40, CD134, OX40L receptor, ACT35, TXGP1L

Alternates names: Fetal liver kinase 1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1

Taglines: Plays an important role in CD4+ and CD8+ T-cells and B-cells response.

NCBI Gene ID #: 3791

NCBI Gene Symbol: VEGFR2

Gene Source: Human

Accession #: P35968

Recombinant: Yes

Source: Insect cells

Purity by SDS-PAGEs: 95%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: < 1.0 EU per/g

Activity (Specifications/test method): N/A

Biological activity: The activity of VEGFR2 D1-7 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml, corresponding to a specific activity of 100,000IU/mg.

Results: 10.0 ng/ml

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 116 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 m filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

Reconstitution Instructions: Reconstitute in sterile water to a concentration not less than 0.1 mg/ml. This solution can then be stored at 4°C for 2-7 days. For future use for future use; For long term storage it is recommended to add a carrier protein (0.1 % HSA or BSA) then store at –20°C. Avoid freeze-thaw cycles.

Amino acid sequence: ASVGLPSVSL DLPRLSIQKD ILTIKANTTL QITCRGQRDL DWLWPNNQSG SEQRVEVTEC SDGLFCKTLT IPKVIGNDTG AYKCFYRETD LASVIYVYVQ DYRSPFIASV SDQHGVVYIT ENKNKTVVIP CLGSISNLNV SLCARYPEKR FVPDGNRISW DSKKGFTIPS YMISYAGMVF CEAKINDESY QSIMYIVVVV GYRIYDVVLS PSHGIELSVG EKLVLNCTAR TELNVGIDFN WEYPSSKHQH KKLVNRDLKT QSGSEMKKFL STLTIDGVTR SDQGLYTCAA SSGLMTKKNS FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP TPQIGEKSLI SPVDSYQYGT TQTLTCTVYA IPPPHHIHWY WQLEEECANE PSQAVSVTNP YPCEEWRSVE DFQGGNKIEV NKNQFALIEG KNKTVSTLVI QAANVSALYK CEAVNKVGRG ERVISFHVTR GPEITLQPDM QPTEQESVSL WCTADRSTFE NLTWYKLGPQ PLPIHVGelP TPVCKNLDTL WKLNATMFSN STNDILIMEL KNASLQDQGD YVCLAQDRKT KKRHCVVRQL TVLERVAPTI TGNLENQTTS IGESIEVSCT ASGNPPPQIM WFKDNETLVE DSGIVLKDGN RNLTIRRVRK EDEGLYTCQA CSVLGCAKVE AFFIIEGA